Victor G. Kramer, Said A Hassounah, S. Colby-Germinario
Feb 11, 2014
Citations
0
Influential Citations
4
Citations
Journal
Journal of the International AIDS Society
Abstract
Cenicriviroc (CVC), a once‐daily, dual CCR5/CCR2 co‐receptor antagonist, has completed Phase 2b development. CVC demonstrated favourable safety and similar efficacy compared with efavirenz (EFV) in Study 202 (NCT01338883); an ex vivo sub‐analysis evaluated treatment effects on HIV entry, measured by intracellular HIV DNA declines, in subjects with virologic success at Week 24. In addition, in vitro assays determined and compared the extent of any cell‐free virion redistribution that CVC or maraviroc (MVC) may cause.